Abstract:Phosphoglycerate mutase 2 (PGAM2) is a critical glycolytic enzyme that is highly expressed in skeletal muscle. In humans, naturally occurring mutations in Phosphoglycerate mutase 2 have been etiologically linked to glycogen storage disease X (GSDX). Phosphoglycerate mutase 2 activity is regulated by several posttranslational modifications such as ubiquitination and acetylation. Here, we report that Phosphoglycerate mutase 2 activity is regulated by sumoylation—a covalent conjugation involved in a wide spectrum of cellular events. We found that Phosphoglycerate mutase 2 contains two primary SUMO acceptor sites, lysine (K)49 and K176, and that the mutation of either K to arginine (R) abolished Phosphoglycerate mutase 2 sumoylation. Given that K176 is more highly evolutionarily conserved across paralogs and orthologs than K49 is, we used the CRISPR-mediated homologous recombination technique in myogenic C2C12 cells to generate homozygous K176R knock-in cells (PGAM2 K176R/K176R ). Compared with wild-type (WT) C2C12 cells, PGAM2 K176R/K176R C2C12 cells exhibited impaired myogenic differentiation, as indicated by decreased differentiation and fusion indexes. Furthermore, the results of glycolytic and mitochondrial stress assays with the XF96 Extracellular Flux analyzer revealed a reduced proton efflux rate (PER), glycolytic PER (glycoPER), extracellular acidification rate (ECAR), and oxygen consumption rate (OCR) in PGAM2 K176R/K176R C2C12 cells, both at baseline and in response to stress. Impaired mitochondrial function was also observed in PGAM2 K176R/K176R P19 cells, a carcinoma cell line. These findings indicate that the PGAM2-K176R mutation impaired glycolysis and mitochondrial function. Gene ontology term analysis of RNA sequencing data further revealed that several downregulated genes in PGAM2 K176R/K176R C2C12 cells were associated with muscle differentiation/development/contraction programs. Finally, PGAM2 with either of two naturally occurring missense mutations linked to GSDX, E89A (conversion of glutamic acid 89 to alanine) or R90W (conversion of arginine 90 to tryptophan), exhibited reduced Phosphoglycerate mutase 2 sumoylation. Thus, sumoylation is an important mechanism that mediates Phosphoglycerate mutase 2 activity and is potentially implicated in Phosphoglycerate mutase 2 mutation-linked disease in humans.

Lysine-372-dependent SUMOylation inhibits the enzymatic activity of glutamine synthases

The Expression Regulation and Characterization of Glutamine Synthetase from the Hyperthermoacidophilic Crenarcheon Sulfolobus Acidocaldarius

Sirtuin-Dependent Reversible Lysine Acetylation Of Glutamine Synthetases Reveals An Autofeedback Loop In Nitrogen Metabolism

Serial Deletion Reveals Structural Basis and Stability for the Core Enzyme Activity of Human Glutaminase 1 Isoforms: Relevance to Excitotoxic Neurodegeneration.

Glutamine Synthetase and Wnt-signaling

Glutamine Synthetase: Localization Dictates Outcome

Production of Glutamine Synthetase in Escherichia Coli Using SUMO Fusion Partner and Application to L-Glutamine Synthesis

Site-directed Mutagenesis of Putative Adenylylation Site of Glutamine Synthetase and Glutamine Production

Regulation of glutamine synthetase activity by transcriptional and posttranslational modifications negatively influences ganoderic acid biosynthesis in Ganoderma lucidum

SUMOylation Activates Large Tumour Suppressor 1 to Maintain the Tissue Homeostasis During Hippo Signalling

Glutaminase in Microglia: A Novel Regulator of Neuroinflammation

Pivotal role of glutamine synthetase in ammonia detoxification

Phosphorylation of Glutamine Synthetase on Threonine 301 Contributes to Its Inactivation During Epilepsy.

Glutamine synthetase as a central element in hepatic glutamine and ammonia metabolism: novel aspects

Sumoylation-deficient phosphoglycerate mutase 2 impairs myogenic differentiation

SUCLA2-coupled regulation of GLS succinylation and activity counteracts oxidative stress in tumor cells

Reversible adenylylation of glutamine synthetase is dynamically counterbalanced during steady-state growth of Escherichia coli

Site-specific inhibition of the small ubiquitin-like modifier (SUMO)-conjugating enzyme Ubc9 selectively impairs SUMO chain formation

Glutamine Synthetase as a Therapeutic Target for Cancer Treatment

SUMOylation of GPS2 protein regulates its transcription-suppressing function.

Glutamine synthetase evolutionary history revisited: Tracing back beyond the Last Universal Common Ancestor